데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
923590-37-8CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1KUQWGLQLLVFLSM-ONAXAZCASA-N923590-37-8DTXSID201029738CHEMBL4525964안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Vaniprevir, which was approved in Japan in 2014 and sold under the trade name Vanihep®, is one of several structurallyrelated macrocycles developed for the treatment of patients afflicted with the hepatitis C virus. Specifically, the drug is indicated for patients with untreated, interferon-unresponsive, or relapsed genotype 1 chronic hepatitis C. Similar to asunaprevir (IV), vaniprevir is a NS3/4A protease inhibitor, and thus has a comparable mechanism of action.
용도Vaniprevir is an antiviral therapy against hepatitis C.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…